LFG
PLRX icon

Larson Financial Group’s Pliant Therapeutics PLRX Stock Holding History

Larson Financial Group’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15
Closed -$20 – 3454
2025
Q1 		$20 Buy
+15
New +$91 ﹤0.01% 3037

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return

Larson Financial Group's PLRX Position: Q2 2025 in Review

Larson Financial Group sold out of Pliant Therapeutics (PLRX) in Q2 2025, closing a stake of 15 shares — an estimated $20 sold.

Larson Financial Group first reported a position in PLRX in Q1 2025 and held it in 1 quarter. The position peaked at $20 in Q1 2025. 114 funds tracked by Wall St. Rank hold PLRX as of Q2 2025.

  • Larson Financial Group reported no remaining Pliant Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Larson Financial Group sold 15 Pliant Therapeutics shares in Q2 2025, an estimated $20.
  • Larson Financial Group first reported a position in Pliant Therapeutics in Q1 2025 and held it in 1 quarter.
  • Larson Financial Group's Pliant Therapeutics position peaked at $20 in Q1 2025.
  • 114 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2025.

Based on Larson Financial Group's 13F filing for Q2 2025, filed 8 Aug 2025.